A Pilot Study of a Ketogenic Diet in Bipolar Disorder: Clinical, Metabolic and Magnetic Resonance Spectroscopy Findings

Participant Eligibility Criteria

Participants were individuals diagnosed with bipolar disorder, according to DSM-IV criteria. Eligibility was contingent upon a period of clinical euthymia lasting at least 3 months, defined by an absence of clinically significant depressive or hypomanic/manic episodes. The age range for participation was 18–70 years. Understanding of English language and residence in Scotland were also required.

Initial Exclusion Criteria

The initial exclusion criteria excluded participants with conditions including pregnancy, breastfeeding, intention to conceive within 3 months, active substance misuse, recent adherence to a ketogenic diet (within the past 2 months), adherence to a vegan diet (vegan ketogenic diet is widely used but our team did not have experience delivering this), recent hospital admission (within the past 3 months), concurrent participation in other research studies, inability to complete baseline assessments, and a history of liver, kidney, or cardiovascular diseases. Severe hyperlipidaemia, indicated by familial hypercholesterolaemia or a total cholesterol level exceeding 7.5 mmol/L, was also an exclusion criterion.

Additional Exclusion Criteria Applied During the Study

As the pilot study progressed, further exclusion criteria were added to address emergent considerations. These were a diagnosis of diabetes, engagement in activities requiring a high energy expenditure (such as long-distance running), and significant recent changes to psychotropic medication use.

Screening and Baseline Procedures

Participants were briefed about the study’s objectives and the eligibility criteria were assessed. On successful screening and consent, baseline assessments were conducted and participants were provided with comprehensive guidelines on adopting and adhering to a ketogenic diet. This included information on potential risks and detailed instructions for diet monitoring. Participants were also required to submit a 3-day food diary and a pre-ketogenic diet information sheet in advance to facilitate the customisation and planning of their diet by the study dietitian.

Assessment and Monitoring

Assessments were conducted at baseline and during the follow-up period (6–8 weeks). Baseline assessment included a review of medical and medication histories, measurements of blood pressure and body mass index (BMI), and completion of a diagnostic interview. Participants also completed several mental health symptom scales, including the Affective Lability Scale 18 (ALS-18), Beck’s Depression Inventory (BDI), and the Young Mania Rating Scale (YMRS). Quality of life was assessed using the Within Trial Resource Use Questionnaire, the EuroQol 5D, and the Work Productivity and Activity Impairment Questionnaire, tailored to capture data on health and social care resource utilisation, household expenditure on food and beverages, and information on employment and absenteeism. Fasting venepuncture and MRS brain scans were conducted pre- and post-intervention. Post-analysis of the study data it was ascertained that one participant had not fasted on the morning of their baseline appointment for venepuncture and MRS. Their data did not present as an outlier for any variable or significantly alter the findings of the study and so remains in the analysis. Data collection was facilitated through both paper questionnaires and a secure online platform, with face-to-face interactions occurring at designated clinical and imaging facilities.

Brain Magnetic Resonance

Brain MR imaging and spectroscopy were acquired using a 3-T clinical MRI scanner (MAGNETOM Prisma, Siemens Healthcare, Erlangen, Germany) with a 32-channel receive head coil. A 3D T1-weighted image (T1w; TR/TE/TI = 2500/4.37/1100 ms, flip angle = 7°, 1.0-mm isotropic resolution) was acquired to facilitate placement of MRS voxels covering the anterior cingulate cortex (ACC; 20 x 20 x 20 mm3, 128 averages, acquisition time 4m26s), right dorsolateral prefrontal cortex (RDLPFC; 30 x 15 x 15 mm3, 96 averages, acquisition time 3m22s) and posterior cingulate cortex (PCC; 20 x 20 x 20 mm3, 128 averages, acquisition time 4m26s). The ACC and RDLPFC were selected as regions of interest (ROIs) based on previous literature implicating these regions in the pathophysiology of bipolar disorder,(15,16) whereas the PCC was selected to generate optimal data quality. At follow up, voxels were automatically placed at the same location using the AutoAlign feature. MRS was obtained using point-resolved spectroscopy (PRESS; TR/TE = 2000/30 ms, flip angle = 90°, receive bandwidth 4000 Hz, 4096 data points, with a single transient acquired without water suppression). Please see supplementary materials for further details.

Daily Monitoring and Rest/Activity Pattern Tracking

Participants engaged in daily self-monitoring of glucose and ketone levels using a KetoMojo device, initially reporting readings via text and later through bluetooth-enabled app syncing. Continuous actigraphy was deployed over a nine-week period to monitor rest/activity patterns, using 50hz AX3 actigraph devices worn in succession for three weeks each. GGIR software was used for accelerometer data processing. Daily ecological momentary assessments (EMA) captured changes in anxiety, mood, energy levels, impulsivity, and speed of thought, initially via text messages and subsequently via an online tool.

Post-intervention Evaluation

Following the intervention, semi-structured telephone interviews were conducted with 15 participants and four research clinicians involved in the study to facilitate a process evaluation, the findings of which are reported separately (17).

Dietary Intervention Protocol

The intervention was a modified ketogenic diet, with a macronutrient distribution of 60–75% calories from fats and 5–7% from carbohydrates, with the remainder sourced from protein. In consideration of blood cholesterol and triglycerides, a preference for unsaturated fats was advised. Adjustments to individual macronutrient ratios were made throughout the study by the study dietitian based on various factors, including the attainment of ketosis defined by a target blood ketone level of 1–4 mmol/L and glucose levels of 4–7.8 mmol/L. In cases where weight loss was both desired and considered safe, a caloric deficit was prescribed to promote body fat as an alternative ketone source. Participants engaged in the diet for a 6–8 week duration, which included an initial adaptation phase, alongside continued standard medical care from their regular healthcare providers.

Dietary Support and Management

Throughout the intervention, participants had weekly remote consultations with a dietitian, supplemented by additional contacts as needed. Participants received guidance to ensure understanding of the diet’s principles, support in adhering to the diet, assistance with troubleshooting dietary challenges and management of potential side effects. The diet plans specified total caloric and macronutrient (in grams) daily intake, portioned accordingly. Customized recipes were provided to align with individual dietary needs. Supervision was continued throughout the diet’s cessation phase, with support offered to those opting to maintain the dietary changes. Behavioural strategies were integrated to enhance diet adherence, including bi-weekly adherence checklists guided by the COM-B framework (which highlights the influence of capability, opportunity, and motivation on behaviour). These have been analysed in a separate process evaluation.(17)

Nutritional Supplementation and Monitoring

Consistent with international nutritional guidelines, participants were counselled on increasing fluid intake and supplementing their diet with a broad-spectrum multivitamin and mineral supplement, along with a calcium and vitamin D supplement. Participants were also educated on managing possible adverse effects, such as hypoglycemia or hyperketosis. Pre-intervention and follow-up health screenings, including analyses of urea and electrolytes, liver function tests, and lipid profiles, were mandatory for all participants. These were carried out to rule out significant hepatic or renal dysfunction or familial hypercholesterolemia and to monitor for adverse changes related to diet, such as alterations in liver function or lipid levels.

Primary and Secondary Outcomes

The primary outcomes of this study assessing feasibility, acceptability and safety have been reported in a previous publication. (14) Here we report the secondary outcome measures (ISRCTN61613198):

• 1. Mood stability measured by the Affective Lability Scale (ALS18) and depression by the Beck Depression Inventory (BDI) at baseline and at 8-week follow-up;

• 2. Hypomania/mania symptoms measured using the Young Mania Rating Scale (YMRS) at baseline and at 8-week follow up;

• 3. Glucose/ketone ratio measured using Ketomojo devices daily throughout the 10-week study period;

• 4. Identification of specific metabolic changes in glucose, ketones and tricarboxylic acid (TCA) metabolites associated with the ketogenic diet, measured using serum and brain MRI measures at baseline and at week 8;

• 5. Mood, energy, speed of thought, impulsivity and anxiety measured using visual analogue scales from 1-100 on daily EMA assessments during the 10 week study period;

• 6. Episodes of bipolar depression and hypomania/mania occurring during the study period assessed by the MINI Neuropsychiatric assessment at baseline and at week 8;

• 7. Sleep duration and circadian activity/rest rhythmicity parameters, assessed by actigraphs throughout the 10-week period (to include 2 weeks of stepping down the diet).

Clinical and Metabolic Outcomes

The statistical analysis used standard methods in SPSS and Excel software (Windows PC version). We calculated mean and median values, standard deviations, and the change from baseline to follow-up for metabolic parameters, BDI, ALS-18 and YMRS values. We used the paired samples t-test function in SPSS to compare the mean at baseline and follow up and determine statistical significance (defined as p <0.05). Available case analysis of all participants who had baseline and follow up measures was performed and the sample size for each variable are given in the results. HOMA-IR was calculated from fasting insulin and glucose levels using the standard equation. (18)

Ecological Momentary Assessment and Analysis

Text messages were used for daily EMA assessment of mood, energy, speed of thought, impulsivity, and anxiety. During the study, the initial EMA rating instructions delivered to participants 1-12 were highlighted by participants as difficult to follow due to inconsistent individual interpretations of normal and pathological ranges on the 100 point scale (e.g., in the mood category participants chose differing ranges between 1-100 to indicate their healthy mood, depression and hypomania, making comparisons unworkable). Thresholds for normal ratings and pathological ratings of depression and (hypo)mania were therefore added to the instructions for patients 13-27 (see supplementary material). Note that EMA analyses were performed only on this second sub-group (n=14).

Metabolomics

Fasting blood samples were taken at baseline appointments and at 6-8 week follow-up appointments. Global metabolomics analysis was performed on a total of 36 serum samples, corresponding to 18 participants who gave a baseline and follow up blood sample and included one unfasted participant. Standard biochemical parameters included HbA1c, C-reactive Protein (CRP), beta-hydroxybutyrate (BHB), insulin, glucose and lipid levels. A more detailed exploratory investigation of untargeted metabolomics was also performed using Rapid HILIC-Z Ion mobility mass spectrometry (RHIMMS) analysis to probe the serum metabolome, annotating a total of 358 metabolic features. Please see supplementary materials for further details.